The Hong Kong Polytechnic University (PolyU) will join forces with Axis Therapeutics, a newly established joint venture by two global biopharmaceutical companies – Athenex, Inc. and Xiangxue Pharmaceutical, to foster the research and development of translational medicine by setting up a Joint Center for Immunotherapy. The Center is set to conduct collaborative research on cancer immunotherapy, with an aim to develop new cancer treatments.
A MoU signing ceremony for setting up the PolyU—Axis Therapeutics Joint Center for Immunotherapy was held on 18 July 2018. PolyU is committed in the innovation and technology development of translational medicine, as well as transferring pioneering research to real-life applications for the benefits of mankind. Over the years, the University has been engaging in the first three new drugs developed in Hong Kong which have succeeded in getting Investigational New Drug (IND) application approval of US Food and Drug Administration (FDA).
For more information, please visit: https://www.polyu.edu.hk/web/en/media/media_releases/index_id_6560.html
A MoU signing ceremony for setting up the PolyU—Axis Therapeutics Joint Center for Immunotherapy was held on 18 July 2018. PolyU is committed in the innovation and technology development of translational medicine, as well as transferring pioneering research to real-life applications for the benefits of mankind. Over the years, the University has been engaging in the first three new drugs developed in Hong Kong which have succeeded in getting Investigational New Drug (IND) application approval of US Food and Drug Administration (FDA).
For more information, please visit: https://www.polyu.edu.hk/web/en/media/media_releases/index_id_6560.html
